76 results about "Antidepressant medication" patented technology

The invention discloses an antidepressant drug compliance management system based on biological feature recognition and a method thereof, and belongs to the field of medical health systems. The system comprises a biological characteristic acquisition module for acquiring multi-modal biological characteristic data of a drug user in real time; the identity authentication module is used for verifying the identity of a medicine user to prevent illegal use or cheating behaviors; the medicine taking behavior management module is responsible for analyzing the behavior sequence of the medicine taking person in real time, identifying the appearance characteristics of the medicine and verifying the accuracy of the medicine taking action; the data analysis module performs cleaning, feature extraction and pattern analysis on the collected data, constructs a personalized medication behavior model and predicts a medication trend; the abnormity monitoring and early warning module is used for carrying out real-time monitoring and risk assessment on medication behaviors through a comprehensive risk assessment mechanism and generating early warning information and intervention suggestions of corresponding levels; and the interaction management module provides a self-adaptive user interface and is responsible for information display, medication reminding pushing and data visual presentation.

The invention belongs to the technical field of biomedicine, and particularly relates to a benzenesulfonamide derivative and application of the benzenesulfonamide derivative in antidepressant drugs. The structural general formula of the compounds is (I), the compounds or pharmaceutically acceptable salts thereof have agonistic activity on 5-hydroxytryptamine 2A type receptors, and the compounds are determined to have good anti-depression activity through a mouse tail suspension experimental model, an open field experimental model and a forced swimming experimental model. The compound is an anti-depression compound which is novel in structure and wide in application prospect, has no magical effect, and can be developed into an anti-depression treatment medicine.

The invention belongs to the technical field of biomedicine, and particularly relates to application of carboline compounds in preparation of antidepressant drugs. According to the present invention, the carboline compound or the pharmaceutically acceptable salt thereof can target the 5-HT2A receptor, and has the 5-HT2A receptor excitation activity; the compound can effectively relieve depression symptoms of mice in a mouse spontaneous activity experiment model, a tail suspension experiment model and an open field experiment model under the dosage of 10 mg / kg-20 mg / kg. As an anti-depression drug, compared with an existing 5-HT2A agonist, the compound has a relatively strong anti-depression effect, but the carboline compound does not have a magical effect and has a prospect of being developed into an anti-depression treatment drug.

The invention relates to the field of biological medicine, in particular to vortioxetine and application of pharmaceutically acceptable salts, solvates, crystal forms and prodrugs of vortioxetine to preparation of drugs for preventing or treating pathogenic fungal infection. The application reveals that the antidepressant vortioxetine (vortioxetine) and hydrobromide thereof (vortioxetine. HBr) which are sold on the market have measurable in-vitro inhibitory activity on various clinical common pathogenic fungi for the first time, so that the pharmacological action spectrum of the compound is expanded, and a new candidate direction is provided for research and development of antifungal drugs; the application not only overcomes the defects of existing antifungal drugs in the aspects of drug resistance, biological membranes and safety, but also opens up a brand new application direction of mental small molecule drugs in the anti-infection field, and has remarkable technical innovation, social value and industrial popularization prospect. The application also provides a theoretical basis for establishing a'multi-modal micromolecular antifungal library ', and can promote the development of pharmacological mechanism research and fungal infection precise treatment.

The present invention relates to a combination, a combination for treating a psychiatric disorder in a patient, a method for treating a psychiatric disorder in a patient, a kit, a dosing regimen, a delivery device, a method of adjuvant therapy, a short-acting magical agent for treating a psychiatric disorder in a patient or a parenteral formulation for treating a psychiatric disorder in a patient. In particular, the present invention relates to the combined administration of a short acting magical agent with a monoamine antidepressant, such as a selective serotonin reuptake inhibitor (SSRI).

The invention discloses a compound with remarkable 5-hydroxytryptamine (5-HT) reuptake inhibition activity, a preparation method of the compound and application of the compound in preparation of anti-depression drugs. And the compound is a compound Oreonudine C. The invention further discloses a preparation method of the compound. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, extracting with chloroform, and performing silica gel column chromatography, C18 ODS column chromatography and preparative high performance liquid chromatography on the chloroform extraction part to obtain the Oreonudine C. The invention further discloses a preparation method of the Oreonudine C. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, and obtaining the Oreonudine C. In-vitro experiments show that the compound Oreonudine C remarkably inhibits reabsorption of 5-HT (the inhibition rate is 60.4%) in mouse hippocampal neuronal cells HT22, and the inhibition rate of the compound Oreonudine C is superior to that of a positive control drug amitriptyline (the inhibition rate is 53.6%). The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.

The application belongs to the technical field of biomedicine, and particularly relates to a benzene sulfonamide derivative and application thereof in antidepressant drugs. The structural general formula of the compound is (I). The compound or a pharmaceutically acceptable salt thereof has agonistic activity on 5-hydroxytryptamine 2A type receptors. The compound is determined to have good antidepressant activity through a mouse tail suspension test model, an open field test model and a forced swimming test model, is a novel antidepressant compound with wide application prospect, has no hallucinogenic effect, and can be developed into an antidepressant therapeutic drug.

The invention provides an application of lilium lancifolium exosome in preparation of a medicine for treating depression. The lilium lancifolium exosome has a unique nano-structure, is better in biocompatibility, can accurately target pathological cells, penetrate a biological membrane and a blood brain barrier, reduces damage to normal cells, directly acts on a central nervous system, is less in dosage, is safer in clinical use, has many side effects when being used as an antidepressant drug, and is high in treatment resistance and recurrence risk, and the like. A brand-new efficient solution is provided, and existing treatment bottlenecks are expected to be broken through.

The invention discloses application of dimethyl fumarate in preparation of a medicine for treating depression, and relates to the technical field of medicine research and development. Comprising experimental verification and medicine preparation, and the medicine preparation comprises the following steps: raw material preparation: weighing a dimethyl fumarate raw material and a medicinal carrier in proportion; uniformly mixing: fully mixing the dimethyl fumarate and the medicinal carrier by using a three-dimensional mixer or a double-cone mixer; granulating: adding a wetting agent for fluidized bed granulation or wet granulation to form granules with set sizes; granulating and drying: granulating the wet granules, drying, and controlling the water content of the granules; forming is conducted; and packaging: packaging the prepared medicine, and labeling information. The dimethyl fumarate is applied to the field of depression treatment, experiments verify that the dimethyl fumarate has a remarkable improvement effect on depression-like behaviors induced by chronic social contusion stress, and a new direction is provided for development of anti-depression drugs.

The invention discloses a fluvoxamine maleate tablet and a preparation method thereof, the fluvoxamine maleate tablet is prepared from the following raw materials in parts by mass: 45 to 55 parts of fluvoxamine maleate, 145 to 155 parts of mannitol, 38 to 42 parts of corn starch, 3 to 8 parts of pregelatinized starch, 0.5 to 1 part of colloidal silicon dioxide and 1.5 to 2 parts of sodium stearyl fumarate, and corn starch accounting for 4.4-5.6% of the total mass is used as a starch slurry raw material. By adopting a wet granulation process, the granules are good in flowability and compressibility, qualified in quality, stable in property, high in release speed and high in solubility, and the dissolution rate of the granules in different pH environments and water media for 15 minutes is greater than 85%. Compared with the traditional antidepressant drug, the fluvoxamine maleate and the pseudoadrenaline have low efficacy and are not easy to cause excitement, hidrosis and other symptoms; the anti-choline and anti-histamine efficacy is low, and the phenomena of weight gain, drowsiness and the like are rarely caused; the interaction among the medicines is small, and the drug combination is facilitated.

The invention relates to application of broad bean pyrimidine in preparation of antidepressant drugs, and belongs to the technical field of biological medicines. Depression is a common and high-disability heavy mental disorder, has the core characteristics of remarkable and lasting emotion lowering and interest loss, seriously damages the social functions and life quality of patients, and has become one of the major public health burdens in the world. Based on new cognition of complex mechanisms of diseases, a new generation of antidepressant drugs which have a brand new action mechanism, can more accurately intervene in core pathological links of the diseases and can better meet the clinical requirements are researched and developed, and the new generation of antidepressant drugs are not only an inevitable direction for promoting psychopharmacology progress, but also are urgent medical necessities for improving prognosis of hundreds of millions of patients and relieving social burdens. A per2- / -mutant zebrafish depression model is used for performing drug screening on traditional Chinese medicine monomers, and finally it is found that 10 mM of broad bean pyrimidine has the anti-depression characteristic and can effectively improve the depression-like phenotype of per2- / -mutant zebrafish.

The present invention relates to combinations, combinations for use, methods of treatment, kits, dosing regimens, delivery devices, adjunctive treatment methods, short-acting psychedelic agents for use, or parenteral formulations for use, for treating mental disorders in patients. In particular, the present invention relates to administering short-acting psychedelic agents in combination with monoamine antidepressants, such as selective serotonin reuptake inhibitors (SSRIs).

The invention belongs to the field of medicines, and relates to application of 3, 5-dimethoxy-4 '-hydroxystilbene in preparation of antidepressant medicines, in particular to a 3, 5-dimethoxy-4'-hydroxystilbene oral preparation and application of the 3, 5-dimethoxy-4 '-hydroxystilbene oral preparation in preparation of rapid and efficient antidepressant medicines, and the component is taken orally and has rapid and remarkable efficacy.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a preparation method of compound radix bupleuri depression-relieving dropping pills and application of the compound radix bupleuri depression-relieving dropping pills in antidepressant drugs. According to the dropping pill preparation, medicine simplification and optimization are carried out on the basis of Xiaoyao powder, meanwhile, the dissolution rate of insoluble components is improved by adopting a solid dispersion technology, the formability and the medicine loading capacity of the dropping pill are optimized by using a compound matrix and a nano flow aid, and the slow-release coating technology meets the slow-release requirement of circadian rhythmic depression. Meanwhile, the dissolution rate and the stability of effective components are improved, and the sustained release characteristic is achieved, so that the composition is suitable for preventing and treating depression.

The invention belongs to the technical field of medicines, and particularly relates to an esketamine and mirtazapine synergistic antidepressant pharmaceutical composition and application thereof. The antidepressant pharmaceutical composition comprises the following active components: esketamine and mirtazapine, the esketamine is an N-methyl-D-aspartic acid receptor antagonist, and the mirtazapine is an adrenergic alpha2-AR antagonist. According to the anti-depression pharmaceutical composition containing esketamine and mirtazapine, through the synergistic effect of esketamine and mirtazapine, the effects of reducing dosage, prolonging aging and reducing adverse reactions are achieved, and major depressive disorder is safely and effectively prevented and treated.

The present invention provides an antidepressant preparation for nasal mucosa administration, its preparation method and application, which relates to the field of medicine. The antidepressant preparation is prepared from the following raw materials: hydroxytyrosol-Angiopep-2 complex, poloxamer, sodium hyaluronate and water; the hydroxytyrosol-Angiopep-2 complex is prepared from hydroxytyrosol and Angiopep-2 with a molar ratio of 1:0.05 to 0.2; the weight-average molecular weight of sodium hyaluronate is 60 to 120 kDa. The antidepressant preparation of the present invention can not only increase the stability of hydroxytyrosol, but also facilitate the delivery of hydroxytyrosol to the brain tissue at a steady rate, directly enter the brain to exert antidepressant efficacy, reduce the number of drug administrations, and better exert the antidepressant activity of hydroxytyrosol. The antidepressant preparation of the present invention has the advantages of long-lasting efficacy and convenient use, and also has the characteristics of good dispersibility, strong adhesion, good stability, and the ability to maintain a local high concentration at the administration site.

The present application relates to novel compounds that are prodrugs of brexpiprazole. The novel compounds of the present invention, upon administration to a subject, undergo chemical conversion by one or more metabolic processes to release the active agent in vivo. Brexpiprazole sold by Rexulti (registered trademark) is an atypical antipsychotic drug, is suitable for being used as an adjuvant therapy of an antidepressant drug, and is used for treating major depressive disorder (MDD) of adults and schizophrenia of adults and children patients over 13 years old. # imgabs0 #

The invention discloses a method for synthesizing amide through oxidative cross-coupling of aldehyde amine driven by visible light and application, and the method comprises the following steps: S100, sequentially adding 20mg of high-crystallinity B / P co-doped g-C3N4 nanosheet, 20mg of potassium carbonate, 20mL of acetonitrile, 1mmol of aldehyde compound and 1mmol of amine compound into a quartz photoreaction flask equipped with magnetic stirring and circulating cooling water, and reacting at room temperature and normal pressure for 2-4 hours; performing dark reaction for 0.5 hour; wherein the B / P co-doped g-C3N4 nanosheet with high crystallinity is used as a heterogeneous photocatalyst; the method comprises the following steps: S101, turning on a 60W blue LED lamp for irradiation, and reacting for 12 hours under the conditions of continuous bubbling and air introduction; wherein the air introduction speed is 1-2 ml / min; and S102, centrifugally separating out the catalyst, drying an organic phase by using anhydrous magnesium sulfate, and carrying out suction filtration and rotary evaporation to obtain a target product, the visible light driven aldehyde amine oxidation cross coupling synthesized amide compound moclobemide prepared by the method can be used as an antidepressant drug and is applied to the field of medicine.

This invention provides a method for predicting antidepressant drugs. Based on a combination of knowledge graph, transcriptomics, and machine learning technologies, it screens potential drugs for depression. Specifically, it integrates disease-related node files, relation files, and transcriptomic data to construct information in triplet form, which is then imported into a model and converted into digital tensor information for scoring. The training dataset includes antidepressant tags from ClinicTrials and DrugBank, as well as other non-antidepressant drugs, combined with differential gene expression data obtained using RNA-seq technology. Multiple scoring models, such as TransE, TransR, DistMult, and ComplEx, are used for training and evaluation to screen potential antidepressant drugs. This method has the advantages of low cost, high efficiency, and wide applicability, significantly improving the accuracy and efficiency of antidepressant drug screening, providing a new drug discovery pathway for the treatment of depression, and helping to accelerate the research and development process of antidepressant drugs.

Milanserin hydrochloride is an effective antidepressant drug, and development of an efficient and green synthetic method for preparing the drug intermediate is of great significance. According to the invention, 2-benzylaniline is adopted as a raw material, and an intermediate compound 7 is obtained with high yield through four steps of reaction of amidation, cyclization, ammonification and reductive amination cyclization. The compound 7 is further converted to obtain a mianserin API molecule, and a high-purity target product can be prepared by further recrystallization. The method has the advantages of high product yield and stable quality; the method has the characteristics of simple operation process and small environmental pollution, and meets the requirements of industrial clean production.

The invention belongs to the field of biological medicine, and particularly relates to a method and a system for curative effect evaluation and drug withdrawal decision support of depression drugs. It has been found that the platelet 5-HT concentration can be used as an objective index of the curative effect of the antidepressant drug and drug withdrawal indication, a drug withdrawal decision-making system based on the platelet 5-HT concentration is constructed, and the platelet 5-HT concentration is combined with the blood concentration of the drug, the HAMD score of a depression patient and basic information of the depression patient. Compared with a conventional decision making system, the specific decision making formula designed by the invention can be used for realizing a more accurate drug withdrawal decision. In addition, a drug withdrawal decision-making system and a drug effect evaluation method based on the platelet 5-HT concentration are combined, and a complete depression drug effect evaluation and drug withdrawal decision-making system suitable for clinical application is developed.

The invention belongs to the technical field of crystal form medicine preparation, and particularly relates to a preparation method of a high-stability vortioxetine hydrobromide crystal form alpha. The vortioxetine hydrobromide is an antidepressant drug which is widely applied at present, and the crystal form alpha of the vortioxetine hydrobromide is relatively high in solubility and relatively good in bioavailability, but the vortioxetine hydrobromide is unstable and is easily transformed into a crystal form beta. The preparation method comprises the following steps: adding vortioxetine hydrobromide into an alcohol-water mixed solution for fully dissolving, applying a direct-current electric field to induce the formation of the crystal form alpha, and controlling the cooling rate to grow the crystal for 1-2 hours, so that the crystal form alpha with high purity and good stability is prepared, does not generate crystal transformation after being placed for a long time, and has better safety when being applied to a clinical preparation.

The invention relates to an anti-depression compound 4-methyl-6-methoxy coumarin, and belongs to the technical field of biological medicines. Depression is the most common mental disorder in the world and is also a main reason for disability. The development of a novel anti-depression drug which is based on a nerve plasticity mechanism, takes effect quickly, has a lasting curative effect and is high in safety, and particularly has important clinical requirements and technical necessity for an effective treatment means for refractory depression. Traditional Chinese medicine monomers and a per2- / -zebra fish depression model are adopted for anti-depression drug screening, and finally it is found that 10 mM of 4-methyl-6-methoxycoumarin has the anti-depression characteristic and has the positive treatment effect on the exploration behavior, social interaction and sleep-awakening period of per2- / -zebra fish. The method can effectively rescue and reverse depression-like phenotypes observed in a per2- / -zebra fish circadian rhythmic depression model, and can restore the balance of important gene expression.

The application belongs to the technical field of medicine, and discloses a combined medicine for treating depression and application thereof. The combined medicine provided by the application comprises an antidepressant and artemisia indica simultaneously administered and / or sequentially administered. The application realizes the antidepressant effect of the combined use of the antidepressant and artemisia indica, effectively prevents and reduces liver injury caused by the antidepressant, expands the user group of the antidepressant, and has important significance in the clinical treatment of depression.

The invention belongs to the technical field of animal model construction, and discloses a construction method of a drug-resistant depression animal model. A Cx43flox / flox mouse is constructed through a CRISPR / Cas9 technology, an AAV virus vector of Cre recombinase encoding a GfaABC1D promoter is further injected into the forehead cortex in a positioned mode, and a model mouse of the forehead cortex with the astrocyte Cx43 being conditionally knocked out is constructed. Through behavioral experiments and inflammatory reaction detection, depression-like behaviors of animals in the model and inflammatory reaction of the forehead cortex are evaluated, and treatment failure of antidepressant drugs on the model is observed. According to the invention, the drug-resistant depression animal model can be stably, simply and repeatedly constructed, and a research basis is provided for research on the pathogenesis of refractory depression and development of antidepressant drugs.

The invention discloses a novel active peptide composition for regulating emotion and application thereof. Belongs to the technical field of active peptides. In the process of extracting new active peptides from brain peptide by taking brain peptide as a raw material, various new active peptides, including VVAVP and VVAVPGN, are found, the efficacy of the new active peptides is further studied, and experimental results show that VVAVP and VVAVPGN have a certain anti-depression effect, but when VVAVP and VVAVPGN synergistically act on mice at the same time according to a ratio of 1: 1-1: 3, the anti-depression effect of VVAVP and VVAVPGN is remarkably improved, and the anti-depression effect of VVAVP and VVAVPGN is remarkably improved. It is accidentally found that the anti-depression effect is multiplied, it is indicated that when fluoxetine and fluoxetine are mixed in a specific proportion, the synergistic effect is achieved in the anti-depression aspect, the anti-depression effect can be remarkably improved, the effect is equivalent to that of fluoxetine in a positive control group, and a new research direction is provided for research and development of anti-depression drugs.

The invention belongs to the technical field of medicines, and particularly relates to an antidepressant pharmaceutical composition and application thereof. The antidepressant pharmaceutical composition is prepared from the following active ingredients: esketamine and mianserin, the esketamine is an N-methyl-D-aspartic acid receptor antagonist, and the mianserin is a central presynaptic adrenergic alpha2-AR antagonist. The invention further discloses a preparation method of the pharmaceutical composition. Escketamine and mianserin play an anti-depression role in different ways, and after combined use, not only is the drug dosage of the escketamine reduced, but also the anti-depression action time of the escketamine is prolonged, and a synergistic amplification effect is generated.

The invention belongs to the technical field of chemical analysis and detection, and particularly relates to a magnetic eutectic solvent, a preparation method and application thereof, and a pretreatment method and a quantitative detection method of wastewater containing antidepressant drugs. The magnetic eutectic solvent provided by the invention comprises a hydrogen bond acceptor, a hydrogen bond donor and cobalt chloride, the hydrogen bond acceptor comprises tri-n-octylphosphine oxide; the hydrogen bond donor comprises aniline, acetamide, ethylene glycol, 1, 3-propylene glycol, thymol or L-menthol; the molar ratio of the hydrogen bond acceptor to the hydrogen bond donor is (1-4): (1-3); the molar ratio of the hydrogen bond acceptor to the cobalt chloride is (1-4): 0.5. The magnetic eutectic solvent provided by the invention has the characteristics of simple preparation and environmental friendliness; the extraction process is simple and convenient and separation is easy to realize when the compound is used as an extraction agent to extract the antidepressant in wastewater, the wastewater pretreatment process is remarkably simplified, and an efficient pretreatment method is provided for accurate detection of trace drug residues in a complex matrix.

The invention relates to the technical field of medicines, in particular to application of artemisia vulgaris in preparation of an anti-depression medicine. According to the application disclosed by the invention, the depression is systematically researched through a chronic depression model induced by chronic unpredictable mild stress (CUMS) and an acute depression model induced by lipopolysaccharide (LPS). Experimental results show that under the stimulation of CUMS or LPS, experimental animals show obvious depression-like behaviors. Compared with a negative control group, depression-like behaviors of mice in the CUMS model group and the LPS model group are confirmed, and behavior abnormalities induced by the two models can be effectively improved after intervention of the artemisinin. Further comparative research finds that the antidepressant effect of the clinically common antidepressant drug venlafaxine with the dosage of 10 mg / kg can be achieved under the dosage of 1 mg / kg of the artemisinin, and the artemisinin has remarkable antidepressant activity. The application has a good application prospect when being applied to the development of anti-depression drugs.

The invention relates to the technical field of gene determination, in particular to an SNP (Single Nucleotide Polymorphism) site detection kit for predicting medication for treating depression, which comprises a data acquisition module, a gene restriction analysis module, a drug recommendation analysis module and a drug recommendation generation module. The gene interpretation data at least comprises a gene interpretation table and a gene drug corresponding table; on the basis of a gene interpretation table, analyzing common metabolism influence of different detection sites on metabolism of the same antidepressant drug, and determining gene comprehensive limitation degrees of different antidepressant drugs and disease-resistant drugs; and based on the gene drug corresponding table, analyzing the burden degree of the disease-resistant drug combination on the metabolic capability of the patient, and determining the recommendation prediction degree of different disease-resistant drugs in combination with the comprehensive limitation degree of the gene, thereby generating a drug recommendation table of the current patient. According to the method, the recommendation prediction degrees of different disease-resistant drugs are accurately determined, so that the accuracy of the generated drug recommendation report is improved.